Resistance in Hepatitis C

Join Stephane Chevaliez, PharmD, PhD; Paul J. Pockros, MD; and Stefan Zeuzem, MD, as they review and discuss key principles of HCV resistance with currently approved direct-acting antiviral agents, the latest resistance data on agents in development, and important considerations for potential future anti-HCV regimens. These expert faculty members also provide practical strategies for clinical challenges with the newly approved direct-acting agents through a case-based analysis.
Stefan Zeuzem, MD
Program Director
person default
Stéphane Chevaliez, PharmD, PhD
Paul J. Pockros, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: October 25, 2011 Expiration: October 24, 2012

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply strategies to reduce the development/expansion of resistance to direct-acting antiviral agents when managing patients receiving treatment with approved direct-acting antiviral agents in combination with peginterferon/ribavirin
  • Integrate key principles regarding antiviral resistance when evaluating data on the direct-acting antiviral agents currently in development
  • Evaluate potential future strategies for HCV treatment based on resistance considerations, including the barrier to resistance and patterns of cross-resistance among classes of direct-acting antiviral agents

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Roche

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has received fees for non-CME services from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Novartis, and Roche; and consulting fees from Abbott, Achillion, Anadys, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, iTherX, Merck, Novartis, Pfizer, Pharmasset, Roche, Santaris, Tibotec, and Vertex.

Faculty

Stéphane Chevaliez, PharmD, PhD

French National Reference Center
for Hepatitis B, C and delta
Department of Virology & INSERM U955
Henri Mondor Hospital
University of Paris 12
Créteil, France

Stephane Chevaliez, PharmD, PhD, has disclosed that he has received grants for research support from Gilead Sciences, and consulting fees from Gilead Sciences, Merck, and Roche.
Paul J. Pockros, MD

Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
Clinical Director of Research, Scripps Translational Science Institute
The Scripps Clinic
La Jolla, California

Paul J. Pockros, MD, has disclosed that he has received grants for research support from Abbott, Bristol-Myers Squibb, Conatus, Genentech, Gilead Sciences, Janssen, Medpace/Mochida, Merck, Pfizer, and Vertex; fees for non-CME services from Bristol-Myers Squibb, Genentech, and Vertex; and consulting fees from Bristol-Myers Squibb, Gilead Sciences, Kadmon, Janssen, Merck, Roche, and Vertex.

Staff

Jennifer M. Blanchette, PhD

Associate Managing Editor

Jennifer M. Blanchette, PhD, has no significant financial relationships to disclose.
Taryn O’Loughlin Gross, PhD

Senior Managing Editor

Taryn O’Loughlin Gross, PhD, has no significant financial relationships to disclose.
Edward King, MA

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no significant financial relationships to disclose.
Anna Poppa

Editorial Contributor

Anna Poppa has disclosed that she has received consulting fees from ViiV Healthcare.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN; and Gordon West, PhD, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians and other healthcare providers involved in the care of patients infected with hepatitis C.

Goal

The goal of this activity is to address the causes and consequences of the emergence of resistance to novel agents for the management of hepatitis C, along with strategies to limit the clinical impact of resistance.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

European physicians can earn their ECMEC®s by completing e-learning programs from accredited CME providers from the United States, that have been certified for AMA PRA Category 1 Credits™. A procedure for the conversion of AMA PRA Category 1 Credits™ into ECMEC®s will be installed when appropriate.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 25, 2011, through October 24, 2012:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

TasP commentary from Alessio Aghemo, MD, PhD, on improving PWID access to HCV treatment by changing restrictive regulatory barriers in Italy

Alessio Aghemo, MD, PhD Released: August 2, 2019

CME/CE/CPE-certified video on strategies for bringing HCV cure to more patients, led by Nancy Reau, MD, from the CCO Hepatitis Annual Meeting

Ira M. Jacobson, MD
Program Director
Jordan J. Feld, MD, MPH Paul Y. Kwo, MD Marion G. Peters, MD, FRACP Nancy Reau, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: August 1, 2019 Expiration: July 31, 2020

Expert commentary from W. David Hardy, MD, featuring guidance on HCV screening and treatment as prevention in MSM, provided by Clinical Care Options

W. David Hardy, MD Released: July 18, 2019

Commentary by Marta Torrens, MD, from Spain on eliminating HCV by optimizing diagnosis, treatment access, and follow-up in high-risk populations.

Marta Torrens, MD Released: July 5, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?